Jyong Biotech (NASDAQ:MENS) Shares Gap Up – What’s Next?

Shares of Jyong Biotech Ltd. (NASDAQ:MENS) gapped up before the market opened on Tuesday . The stock had previously closed at $27.20, but opened at $30.00. Jyong Biotech shares last traded at $29.48, with a volume of 3,635 shares.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Jyong Biotech in a report on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has a consensus rating of “Sell”.

Jyong Biotech Trading Down 0.2%

The stock’s 50 day moving average is $45.82.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Jyong Biotech stock. BNP Paribas Financial Markets bought a new stake in shares of Jyong Biotech Ltd. (NASDAQ:MENS) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 1,698 shares of the company’s stock, valued at approximately $67,000.

About Jyong Biotech

OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers’ health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.